BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Tuesday, 19 August 1997.
"Around-the-clock monitoring of our filtration plants and regular tests of our source water are major factors in the high quality of Southern California's drinking water," said Metropolitan General Manager John R. Wodraska.
"Further reducing the region's already low risk is our Cryptosporidium Action Plan, which has made important progress in dealing with this potentially deadly organism," Wodraska said.
Cryptosporidium is a microscopic protozoan responsible for sporadic outbreaks of waterborne illness around the world. Traditional drinking water disinfectants such as chlorine are ineffective against the organism. Additionally, there is no effective medication for Cryptosporidiosis , a disease that can cause flu-like symptoms in healthy people but prove fatal to people with suppressed immune systems .
Mark D. Beuhler, director of water quality for Metropolitan, said the district's $3.3 million Cryptosporidium Action Plan has focused on tightening the district's filtration and treatment procedures; increased monitoring of source water; research; and public education.
"Information developed by the Action Plan will allow Metropolitan and its 27 member agencies to increase the region's protection against Crypto and to influence national policy with sound scientific data," Beuhler said.
NOTE TO EDITORS: The Metropolitan Water District is a regional water agency that imports water from Northern California and the Colorado River, and delivers it on a wholesale basis to the coastal plain of Southern California. Through its 27 member public agencies, the district provides almost 60 percent of the water used by nearly 16 million people living in portions of Los Angeles, Orange, Riverside, San Bernardino, San Diego and Ventura counties.
CONTACT: Metropolitan Water District of Southern California Bob Gomperz, 213/217-6866 Home, 818/797-5478 rgomperz@mwd.dst.ca.us or Bob Muir, 213/217-6930 Home, 714/879-7478 rmuir@mwd.dst.ca.us or Rob Hallwachs, 213/217-6450 Home, 818/398-7697 rhallwachs@mwd.dst.ca.us or Sal Vazquez, 213/217-6752 Home, 818/951-4364 svazquez@mwd.dst.ca.us
Copyright (c) 1997/BUSINESS WIRE. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854.
970819
BW970816
ÆGIS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.
ÆGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2003. AEGiS. All materials appearing on ÆGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of ÆGiS, or the party credited as the provider of the content.